These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 15190385

  • 1. The soluble tumor necrosis factor receptor etanercept: a new strategy for the treatment of autoimmune rheumatic disease.
    Cole P, Rabasseda X.
    Drugs Today (Barc); 2004 Apr; 40(4):281-324. PubMed ID: 15190385
    [Abstract] [Full Text] [Related]

  • 2. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.
    Culy CR, Keating GM.
    Drugs; 2002 Apr; 62(17):2493-537. PubMed ID: 12421111
    [Abstract] [Full Text] [Related]

  • 3. Etanercept: a review of its use in the management of rheumatoid arthritis.
    Dhillon S, Lyseng-Williamson KA, Scott LJ.
    Drugs; 2007 Apr; 67(8):1211-41. PubMed ID: 17521223
    [Abstract] [Full Text] [Related]

  • 4. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [Abstract] [Full Text] [Related]

  • 5. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.
    Benucci M, Li Gobbi F, Sabadini L, Saviola G, Baiardi P, Manfredi M.
    Int J Immunopathol Pharmacol; 2009 Oct; 22(4):1147-52. PubMed ID: 20074482
    [Abstract] [Full Text] [Related]

  • 6. Spotlight on etanercept in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.
    Culy CR, Keating GM.
    BioDrugs; 2003 Oct; 17(2):139-45. PubMed ID: 12641492
    [Abstract] [Full Text] [Related]

  • 7. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein.
    Zhou H.
    J Clin Pharmacol; 2005 May; 45(5):490-7. PubMed ID: 15831771
    [Abstract] [Full Text] [Related]

  • 8. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.
    Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, Miranda P, Park MC, Pavelka K, Pedersen R, Szumski A, Hammond C, Koenig AS, Vlahos B.
    Lancet; 2013 Mar 16; 381(9870):918-29. PubMed ID: 23332236
    [Abstract] [Full Text] [Related]

  • 9. Etanercept (Enbrel) -- an update.
    Goffe B.
    Skin Therapy Lett; 2013 Mar 16; 9(10):1-4, 9. PubMed ID: 15657632
    [Abstract] [Full Text] [Related]

  • 10. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations.
    Kremer JM, Weinblatt ME, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Jackson CG, Atkins KM, Feng A, Burge DJ.
    Arthritis Rheum; 2003 Jun 16; 48(6):1493-9. PubMed ID: 12794815
    [Abstract] [Full Text] [Related]

  • 11. Treating to target with etanercept in rheumatoid arthritis: cost-effectiveness of dose reductions when remission is achieved.
    Kobelt G.
    Value Health; 2014 Jul 16; 17(5):537-44. PubMed ID: 25128046
    [Abstract] [Full Text] [Related]

  • 12. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.
    Nuijten MJ, Engelfriet P, Duijn K, Bruijn G, Wierz D, Koopmanschap M.
    Pharmacoeconomics; 2001 Jul 16; 19(10):1051-64. PubMed ID: 11735673
    [Abstract] [Full Text] [Related]

  • 13. [New drugs and treatment strategies for rheumatoid arthritis].
    Fantini F.
    Recenti Prog Med; 2003 Sep 16; 94(9):361-79. PubMed ID: 12942798
    [Abstract] [Full Text] [Related]

  • 14. Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis.
    Cobo-Ibáñez T, Martín-Mola E.
    Expert Opin Pharmacother; 2007 Jun 16; 8(9):1373-97. PubMed ID: 17563271
    [Abstract] [Full Text] [Related]

  • 15. [Therapy of rheumatoid arthritis with etanercept].
    Lamprecht P, Nitschmann S.
    Internist (Berl); 2009 May 16; 50(5):633-4. PubMed ID: 19350212
    [No Abstract] [Full Text] [Related]

  • 16. COMET's path, and the new biologicals in rheumatoid arthritis.
    Kremer JM.
    Lancet; 2008 Aug 02; 372(9636):347-8. PubMed ID: 18635257
    [No Abstract] [Full Text] [Related]

  • 17. Etanercept in arthritis.
    Scott DL.
    Int J Clin Pract; 2005 Jan 02; 59(1):114-8. PubMed ID: 15707475
    [Abstract] [Full Text] [Related]

  • 18. Tumour necrosis factor-alpha blockers in rheumatoid arthritis: review of the clinical experience.
    Richard-Miceli C, Dougados M.
    BioDrugs; 2001 Jan 02; 15(4):251-9. PubMed ID: 11437690
    [Abstract] [Full Text] [Related]

  • 19. Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease.
    Shanahan JC, St Clair W.
    Clin Immunol; 2002 Jun 02; 103(3 Pt 1):231-42. PubMed ID: 12173297
    [Abstract] [Full Text] [Related]

  • 20. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.
    Spalding JR, Hay J.
    Pharmacoeconomics; 2006 Jun 02; 24(12):1221-32. PubMed ID: 17129076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.